ArticleBMC cancer2025
A deep learning model for classification of chondroid tumors on CT images.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Performance comparison and future perspectives of deep learning and classical machine learning in bone tumor applications: a systematic review (2019-2025).BMC medical informatics and decision making · 2026Pooled it
- Article
- A comprehensive deep learning approach to improve enchondroma detection on X-ray images.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDifferentiating chondroid tumors is crucial for proper patient management. This study aimed to develop a deep learning model (DLM) for classifying enchondromas, atypical cartilaginous tumors (ACT), and high-grade chondrosarcomas using CT images.
methodsThis retrospective study analyzed chondroid tumors from two independent cohorts. Tumors were segmented on CT images. A 2D convolutional neural network was developed and tested using split-sample and geographical validation. Four radiologists blinded to patient data and the DLM results with various levels of experience performed readings of the external test dataset for comparison. Performance metrics included accuracy, sensitivity, specificity, and area under the curve (AUC).
resultsCTs from 344 patients (175 women; age = 50.3 ± 14.3 years;) with diagnosed enchondroma (n = 124), ACT (n = 92) or high-grade chondrosarcoma (n = 128) were analyzed. The DLM demonstrated comparable performance to radiologists (p > 0.05), achieving an AUC of 0.88 for distinguishing enchondromas from chondrosarcomas and 0.82 for differentiating enchondromas from ACTs. The DLM and musculoskeletal expert showed similar performance in differentiating ACTs from high-grade chondrosarcomas (p = 0.26), with an AUC of 0.64 and 0.56, respectively.
conclusionsThe DLM reliably differentiates benign from malignant cartilaginous tumors and is particularly useful for the differentiation between ACTs and Enchondromas, which is challenging based on CT images only. However, the differentiation between ACTs and high-grade chondrosarcomas remains difficult, reflecting known diagnostic challenges in radiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.